Single Dose Intravesical Apaziquone Postoperative in Patients Undergoing TURBT for Noninvasive Bladder Cancer (SPI-611)
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the 2-Year Recurrence Rate of bladder cancer in
randomized patients with tumor histology Ta, G1-G2 who received TransUrethral Resection of
Bladder Tumor (TURBT) plus apaziquone versus those who received TURBT plus placebo.